Bellerophon Therapeutics Inc
(BLPH)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,490 | 10,682 | 15,577 | 7,329 | 11,721 |
| TOTAL | $4,979 | $11,245 | $15,771 | $7,563 | $12,059 |
| Non-Current Assets | |||||
| PPE Net | N/A | N/A | 1 | 2 | 6 |
| Other Non-Current Assets | 0 | 0 | 194 | 370 | 543 |
| TOTAL | $N/A | $N/A | $195 | $372 | $549 |
| Total Assets | $4,979 | $11,245 | $15,966 | $7,935 | $12,608 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 612 | 1,887 | 1,070 | 1,230 | 1,525 |
| Accrued Expenses | 644 | 3,735 | 4,286 | 3,968 | 3,258 |
| TOTAL | $1,256 | $5,622 | $5,364 | $5,401 | $5,179 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 1 |
| TOTAL | $N/A | $N/A | $N/A | $N/A | $1 |
| Total Liabilities | $1,256 | $5,622 | $5,364 | $5,401 | $5,180 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 12,233 | 12,233 | 10,450 | 10,448 | 9,545 |
| Common Shares | 122 | 122 | 104 | 96 | 95 |
| Retained earnings | -256,315 | -254,394 | -249,256 | -252,078 | -247,062 |
| TOTAL | $3,723 | $5,623 | $10,602 | $2,534 | $7,428 |
| Total Liabilities And Equity | $4,979 | $11,245 | $15,966 | $7,935 | $12,608 |